Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma

21 Feb 2020

Abstract excerpt

Immune checkpoint blockade (ICB) therapies that target programmed cell death 1 (PD1) and PD1 ligand 1 (PDL1) have demonstrated promising benefits in lung adenocarcinoma (LUAD), and tumor mutational burden (TMB) is the most robust biomarker associated with the efficacy of PD-1-PD-L1 axis blockade in LUAD, but the assessment of TMB by whole-exome sequencing (WES) is rather expensive and time-consuming. Although...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32154170
DOI: 10.3389/fonc.2020.00168

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung AdenocarcinomaPMID 32154170Read ↗

Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study.Semantic proximity Read ↗

Molecular architecture of the tumor microenvironment caused by BRCA1 and BRCA2 somatic mutations in human lung adenocarcinoma.Semantic proximity Read ↗

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung CancerSemantic proximity Read ↗

Molecular architecture of the tumor microenvironment caused by <i>BRCA1</i> and <i>BRCA2</i> somatic mutations in lung adenocarcinomaSemantic proximity Read ↗

DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma.Semantic proximity Read ↗

B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.Semantic proximity Read ↗

COL22A1 and DNAH8 mutations are associated with tumor mutation burden and prognosis of lung adenocarcinoma patientsSemantic proximity Read ↗

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.Semantic proximity Read ↗

MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinomaSemantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read ↗

Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.